Rhumbline Advisers Bio Line Rx Ltd. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Rhumbline Advisers holds 32,611 shares of BLRX stock, worth $4,565. This represents 0.0% of its overall portfolio holdings.

Number of Shares

32,611

Previous 25,741 26.69%

Holding current value

$4,565

Previous $14,000 21.43%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.53 - $0.87 $3,641 - $5,976	6,870 Added 26.69%	32,611 $17,000
Q2 2024 Aug 01, 2024	BUY	$0.56 - $0.86 $4,149 - $6,371	7,409 Added 40.42%	25,741 $14,000
Q1 2024 May 09, 2024	SELL	$1.03 - $1.56 $479 - $726	-466 Reduced 2.48%	18,332 $20,000
Q4 2023 Feb 08, 2024	BUY	$1.31 - $1.86 $4,529 - $6,431	3,458 Added 22.54%	18,798 $29,000
Q3 2023 Nov 09, 2023	BUY	$1.23 - $2.45 $2,158 - $4,299	1,755 Added 12.92%	15,340 $27,000
Q2 2023 Aug 08, 2023	BUY	$0.96 - $1.78 $13,041 - $24,181	13,585 New	13,585 $21,000
Q3 2022 Nov 10, 2022	BUY	$0.88 - $1.91 $2,229 - $4,838	2,533 Added 17.4%	17,092 $16,000
Q3 2021 Nov 12, 2021	BUY	$2.65 - $3.35 $2,316 - $2,927	874 Added 6.39%	14,559 $40,000
Q1 2021 May 06, 2021	SELL	$2.38 - $4.0 $1,244 - $2,092	-523 Reduced 3.68%	13,685 $38,000
Q4 2020 Feb 10, 2021	BUY	$1.47 - $3.62 $20,885 - $51,432	14,208 New	14,208 $36,000
Q3 2019 Oct 23, 2019	SELL	$2.56 - $5.25 $32,542 - $66,738	-12,712 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$4.95 - $6.45 $62,924 - $81,992	12,712 New	12,712 $5,000

Others Institutions Holding BLRX

# of Institutions

Shares Held

3.38M

Call Options Held

46.5K

Put Options Held

6.3K

View Full List

About BioLineRx Ltd.

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $8.61M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

More about BLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Bio Line Rx Ltd. Transaction History